Market Research Logo

Dyslipidemia - Pipeline Review, H1 2015

Dyslipidemia - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Dyslipidemia - Pipeline Review, H1 2015’, provides an overview of the Dyslipidemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Dyslipidemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Dyslipidemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Dyslipidemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Dyslipidemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Dyslipidemia Overview
Therapeutics Development
Pipeline Products for Dyslipidemia - Overview
Pipeline Products for Dyslipidemia - Comparative Analysis
Dyslipidemia - Therapeutics under Development by Companies
Dyslipidemia - Therapeutics under Investigation by Universities/Institutes
Dyslipidemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Dyslipidemia - Products under Development by Companies
Dyslipidemia - Products under Investigation by Universities/Institutes
Dyslipidemia - Companies Involved in Therapeutics Development
Amgen Inc.
Arisaph Pharmaceuticals, Inc.
AstraZeneca PLC
Biocon Limited
Cadila Pharmaceuticals Ltd.
Cerenis Therapeutics Holding SA
Chong Kun Dang Pharmaceutical Corp.
CymaBay Therapeutics, Inc.
Daiichi Sankyo Company, Limited
Debiopharm International S.A.
Dezima Pharma BV
Dr. Reddy's Laboratories Limited
Genfit SA
GlaxoSmithKline plc
Hanmi Pharmaceuticals, Co. Ltd.
High Point Pharmaceuticals, LLC
Intas Pharmaceuticals Ltd.
Jenrin Discovery, Inc.
JW Pharmaceutical Corporation
Kissei Pharmaceutical Co., Ltd.
Kotobuki Pharmaceutical Co., Ltd.
Kowa Company, Ltd.
Kymab Limited
Lipicard Technologies Limited
Merck & Co., Inc.
Nippon Chemiphar Co., Ltd.
Novartis AG
Pfizer Inc.
Pharmena SA
Piramal Enterprises Limited
Reviva Pharmaceuticals Inc.
Sanofi
Takeda Pharmaceutical Company Limited
Torrent Pharmaceuticals Limited
Zydus Cadila Healthcare Limited
Dyslipidemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(ezetimibe + rosuvastatin calcium) - Drug Profile
(niacin + aspirin) - Drug Profile
(pitavastatin + valsartan) - Drug Profile
(rosuvastatin calcium + ezetimibe) - Drug Profile
(statin + niacin + aspirin) - Drug Profile
4655-K09 - Drug Profile
anacetrapib - Drug Profile
ARI-3037MO - Drug Profile
AZ-12260493 - Drug Profile
BioE-1115 - Drug Profile
bococizumab - Drug Profile
BSN-852 - Drug Profile
C-24 - Drug Profile
C-3 - Drug Profile
Centatin - Drug Profile
CKD-519 - Drug Profile
Debio-0930B - Drug Profile
DEZ-001 - Drug Profile
DF-461 - Drug Profile
DGAT-1 - Drug Profile
DRL-17822 - Drug Profile
evolocumab - Drug Profile
GFT-505 - Drug Profile
GSK-2041706 - Drug Profile
HCP-1105 - Drug Profile
HCP-1305 - Drug Profile
HDL Receptor Enhancer - Drug Profile
HPP-593 - Drug Profile
INSUPR-001 - Drug Profile
JD-5037 - Drug Profile
K-312 - Drug Profile
K-877 - Drug Profile
KT6-971 - Drug Profile
KTA-439 - Drug Profile
KY-1020 - Drug Profile
LP-071 - Drug Profile
LT-5421 - Drug Profile
LT-5423 - Drug Profile
MAT-9001 - Drug Profile
MBX-8025 - Drug Profile
MGL-3196 - Drug Profile
NC-2400 - Drug Profile
ND-630 - Drug Profile
ND-654 - Drug Profile
P-7435 - Drug Profile
Peroxibrate - Drug Profile
pitavastatin CR - Drug Profile
Recombinant ApoE4 for Dyslipidemia - Drug Profile
RP-17000 - Drug Profile
Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase Inhibitor for Obesity, Dyslipidemia and Type 2 Diabetes - Drug Profile
Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase Inhibitor for Obesity Dyslipidemia and Type 2 Diabetes - Drug Profile
Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia - Drug Profile
Small Molecule to Inhibit Farnesoid X Receptor for Dyslipidemia - Drug Profile
Small Molecules for Dyslipidemia and Hypertriglyceridemia - Drug Profile
Small Molecules to Inhibit DGAT-1 for Dyslipidemia and Obesity - Drug Profile
Small Molecules to Inhibit DGAT-1 for Metabolic Disorders - Drug Profile
Small Molecules to Inhibit Endothelial Lipase for Dyslipidemia - Drug Profile
SPX-100 - Drug Profile
SPX-8522876 - Drug Profile
Synthetic Peptides for Dyslipidemic and Vascular Disorders - Drug Profile
TAP-311 - Drug Profile
TRC-210258 - Drug Profile
TRIA-662 - Drug Profile
VK-0214 - Drug Profile
ZLN-005 - Drug Profile
ZLN-024 - Drug Profile
ZYH-7 - Drug Profile
ZYT-1 - Drug Profile
Dyslipidemia - Recent Pipeline Updates
Dyslipidemia - Dormant Projects
Dyslipidemia - Discontinued Products
Dyslipidemia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Dyslipidemia, H1 2015
Number of Products under Development for Dyslipidemia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2015
Dyslipidemia - Pipeline by Amgen Inc., H1 2015
Dyslipidemia - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2015
Dyslipidemia - Pipeline by AstraZeneca PLC, H1 2015
Dyslipidemia - Pipeline by Biocon Limited, H1 2015
Dyslipidemia - Pipeline by Cadila Pharmaceuticals Ltd., H1 2015
Dyslipidemia - Pipeline by Cerenis Therapeutics Holding SA, H1 2015
Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015
Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H1 2015
Dyslipidemia - Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Dyslipidemia - Pipeline by Debiopharm International S.A., H1 2015
Dyslipidemia - Pipeline by Dezima Pharma BV , H1 2015
Dyslipidemia - Pipeline by Dr. Reddy's Laboratories Limited, H1 2015
Dyslipidemia - Pipeline by Genfit SA, H1 2015
Dyslipidemia - Pipeline by GlaxoSmithKline plc, H1 2015
Dyslipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015
Dyslipidemia - Pipeline by High Point Pharmaceuticals, LLC, H1 2015
Dyslipidemia - Pipeline by Intas Pharmaceuticals Ltd., H1 2015
Dyslipidemia - Pipeline by Jenrin Discovery, Inc., H1 2015
Dyslipidemia - Pipeline by JW Pharmaceutical Corporation, H1 2015
Dyslipidemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015
Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co., Ltd., H1 2015
Dyslipidemia - Pipeline by Kowa Company, Ltd., H1 2015
Dyslipidemia - Pipeline by Kymab Limited, H1 2015
Dyslipidemia - Pipeline by Lipicard Technologies Limited, H1 2015
Dyslipidemia - Pipeline by Merck & Co., Inc., H1 2015
Dyslipidemia - Pipeline by Nippon Chemiphar Co., Ltd., H1 2015
Dyslipidemia - Pipeline by Novartis AG, H1 2015
Dyslipidemia - Pipeline by Pfizer Inc., H1 2015
Dyslipidemia - Pipeline by Pharmena SA, H1 2015
Dyslipidemia - Pipeline by Piramal Enterprises Limited, H1 2015
Dyslipidemia - Pipeline by Reviva Pharmaceuticals Inc., H1 2015
Dyslipidemia - Pipeline by Sanofi, H1 2015
Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Dyslipidemia - Pipeline by Torrent Pharmaceuticals Limited, H1 2015
Dyslipidemia - Pipeline by Zydus Cadila Healthcare Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Dyslipidemia Therapeutics - Recent Pipeline Updates, H1 2015
Dyslipidemia - Dormant Projects, H1 2015
Dyslipidemia - Dormant Projects (Contd..1), H1 2015
Dyslipidemia - Dormant Projects (Contd..2), H1 2015
Dyslipidemia - Dormant Projects (Contd..3), H1 2015
Dyslipidemia - Dormant Projects (Contd..4), H1 2015
Dyslipidemia - Dormant Projects (Contd..5), H1 2015
Dyslipidemia - Dormant Projects (Contd..6), H1 2015
Dyslipidemia - Discontinued Products, H1 2015
Dyslipidemia - Discontinued Products (Contd..1), H1 2015
Dyslipidemia - Discontinued Products (Contd..2), H1 2015
Dyslipidemia - Discontinued Products (Contd..3), H1 2015
Dyslipidemia - Discontinued Products (Contd..4), H1 2015
List of Figures
Number of Products under Development for Dyslipidemia, H1 2015
Number of Products under Development for Dyslipidemia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report